Intraperitoneal administration of recombinant human Trx-1 (hTrx-1) protected brain damage from ischemic stroke [7], while reducing the level of Trx-1 by small interfering RNA deteriorated the cerebral injury [8]. The gene discussed is KMT2A; the disease is ischemic stroke.